The ABPI is at the heart of a health sector-wide effort to establish consensus on key Brexit issues including medicines regulation, UK and EU trading relationships, access to talent, and the future of UK science.
The objectives of this work are to ensure that patients and public health are central to...
The UK has robust measures in place to ensure that medicines and vaccines are both clinically and cost effective before they can be used in the NHS.
Illness never sleeps. It grows, mutates and causes pain and suffering. Disease never takes a break, so neither do we. Because people fighting disease deserve the best chance to live.
The ABPI has produced this sourcebook to support pharmaceutical companies in working successfully and collaboratively with patients and patient organisations.
Medicines and vaccines are some of the most important ways we have to fight disease on a global scale and keep people fit and healthy.
13 December 2019
The ABPI has welcomed the news that the Conservative Party have won a majority and looks forward to working with the new Government.
06 December 2019
Now that the Party manifestos have now been published, we’ve analysed how their policies will impact the pharmaceutical sector in the UK.
02 December 2019
The ABPI has appointed Dr Richard Torbett as its new Chief Executive. He'll take up the job from 1 January.
28 November 2019
Our analysis of the SNP General Election manifesto.
06 January 2020
Recommendations have been published in the British Journal of Cancer on how best to conduct Complex Innovative Design (CID) trials. Dr Ali Hansford, Head of Regulatory Strategy Policy, looks into these recommendations in more detail.
15 November 2019
The ABPI's President Haseeb Ahmad has written a comment piece on the launch of our 2020 Manifesto for Medicine.